NOT-TR-24-028: Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Notice Number:

NOT-TR-24-028

Key Dates

Release Date:

June 24, 2024

Estimated Publication Date of Notice of Funding Opportunity :

October 18, 2024

First Estimated Application Due Date:

February 17, 2025

Earliest Estimated Award Date:

October 01, 2025

Earliest Estimated Start Date:

December 01, 2025

Related Announcements

May 09, 2022 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). See NOFO PAR-22-167

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The National Center for Advancing Translational Sciences (NCATS) intends to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) entitled, “Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional).”

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The NOFO is expected to be published in the Fall of 2024 with an expected application due date in Winter 2025.

The NOFO will again utilize the UG3/UH3 activity code.

Please review the CCIA webpage for more Information.

Research Initiative Details

The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration (CCIA) Award supports synergistic activities that accelerate the translational research process through collaboration and innovation. The purpose of this notice of funding opportunity announcement (NOFO) is to invite applicants to develop, demonstrate and disseminate innovative solutions that transform the field of translational science by addressing the inefficiencies that are common across diseases through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders. By emphasizing innovation and collaborative science, the CTSA serves as a catalyst to enable all entities in the translational research enterprise to work more efficiently and effectively to bring more treatments to all people more quickly.

NIH is implementing a simplified framework for the peer review for the majority of competing research project grant (RPG) applications, beginning with submissions with due dates after January 25, 2025. These changes will include UG3/UH3 applications submitted in response to the re-issuance of this NOFO. Potential applicants are encouraged to review this new review policy in advance.

Funding Information

Estimated Total Funding

NCATS intends to commit up to $5 million per Fiscal Year for the CCIA Awards.

Expected Number of Awards

TBD

Estimated Award Ceiling

Up to $650,000 direct cost annual budget for both UG3/UH3 Phases.

Primary Assistance Listing Number(s)

93.350

Anticipated Eligible Organizations

Only active CTSA Hub prime and partnering organizations are eligible to apply

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Kristopher Bough, PhD
National Center for Advancing Translational Sciences (NCATS)
Division of Clinical Innovation (DCI)
Email: [email protected]